​Effective November 1, 2021, the generic injectable treprostinil product manufactured by Sandoz will be considered the Independence preferred injectable treprostinil product for the treatment of pulmonary arterial hypertension. Generic drugs are FDA-approved to be safe and effective.

Our specialty pharmacy vendors currently distribute the Sandoz generic. This ensures that our network providers and their patients will have reliable access to the preferred product.​